TrialEBioMedicine2022

Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.

Odile Launay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.